-
公开(公告)号：US08703738B2
公开(公告)日：2014-04-22
申请号：US13611753
申请日：2012-09-12
IPC分类号： A61K31/715
CPC分类号： C08B37/00 , A61K31/715 , A61L27/34 , A61L31/10 , C08L5/00
摘要： The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
摘要翻译： 本发明涉及通式（I）的新生物素化的十六碳糖，其中：Biot是生物素衍生物; R，R 1和R 2彼此独立地表示C 1 -C 6烷氧基或-OSO 3; R3表示C1-C6烷氧基或-OSO3，或R3构成-O-CH2-桥; Pe表示糖连接; 以及它们的药学上可接受的盐，以及它们作为药物的用途。
-
公开(公告)号：US20130004551A1
公开(公告)日：2013-01-03
申请号：US13611753
申请日：2012-09-12
CPC分类号： C08B37/00 , A61K31/715 , A61L27/34 , A61L31/10 , C08L5/00
摘要： The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
摘要翻译： 本发明涉及通式（I）的新生物素化的十六碳糖，其中：Biot是生物素衍生物; R，R 1和R 2彼此独立地表示C 1 -C 6烷氧基或-OSO 3; R3表示C1-C6烷氧基或-OSO3，或R3构成-O-CH2-桥; Pe表示糖连接; 以及它们的药学上可接受的盐，以及它们作为药物的用途。
-
公开(公告)号：US08557968B2
公开(公告)日：2013-10-15
申请号：US12837861
申请日：2010-07-16
CPC分类号： C08B37/00 , A61K31/715 , A61L27/34 , A61L31/10 , C08L5/00
摘要： The invention concerns novel biotinylated hexadecasaccharides of general formula (I) wherein: Biot is a biotin derivative; R, R1 and R2, represent independently of one another a C1-C6 alkoxy or and —OSO3; R3 represents a C1-C6 alkoxy or an —OSO3, or R3 constitutes a —O—CH2— bridge; Pe represents a saccharide concatenation; as well as their pharmaceutically acceptable salts, and their use as medicines.
摘要翻译： 本发明涉及通式（I）的新生物素化的十六碳糖，其中：Biot是生物素衍生物; R，R 1和R 2彼此独立地表示C 1 -C 6烷氧基或-OSO 3; R3表示C1-C6烷氧基或-OSO3，或R3构成-O-CH2-桥; Pe表示糖连接; 以及它们的药学上可接受的盐，以及它们作为药物的用途。
-
4.发明授权Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative 有权具有抗血栓活性的多糖与生物素或生物素衍生物至少包含一个共价键公开(公告)号：US07943595B2
公开(公告)日：2011-05-17
申请号：US11035717
申请日：2005-01-14
IPC分类号： A61K31/715 , C07K17/10
CPC分类号： C08B37/006 , A61K31/715 , C08B37/00 , C08B37/0063
摘要： The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
摘要翻译： 本发明涉及具有与生物素或生物素衍生物至少一个共价键的抗血栓形成活性的新型合成多糖以及使用抗生物素蛋白或链霉抗生物素蛋白的方法，其可以中和这些多糖。
-
5.发明授权公开(公告)号：US07919614B2
公开(公告)日：2011-04-05
申请号：US10677894
申请日：2003-10-02
IPC分类号： A61K31/716 , A61K31/737 , C08B11/02 , C07H5/10 , C07H15/04
CPC分类号： C08B37/006 , A61K31/435 , A61K31/445 , A61K31/505 , A61K31/60 , A61K31/715 , A61K45/06 , C08B37/00
摘要： Synthetic polysaccharides are disclosed containing 8-24 monosaccharide units made up of a concatenation of disaccharides consisting of a uronic acid and a hexose, wherein the hydroxyl groups of the polysaccharides are etherified with a C1-6 alkyl group or esterified in the form of a sulpho group, each disaccharide being at least monoetherified; and salts thereof, are disclosed.
摘要翻译： 公开了合成多糖，其含有由糖醛酸和己糖组成的二糖的连接构成的8-24个单糖单元，其中多糖的羟基用C 1-6烷基醚化或以磺酸形式酯化 组，每个二糖至少单醚化; 及其盐。
-
6.发明授权公开(公告)号：US06534481B1
公开(公告)日：2003-03-18
申请号：US09230139
申请日：1999-09-07
申请人： Pierre Alexandre Driguez , Philippe Duchaussoy , Jean Marc Herbert , Maurice Petitou , Constant Van Boeckel , Peter Grootenhuis , Johannes Basten , Cornelia Dreef-Tromp
发明人： Pierre Alexandre Driguez , Philippe Duchaussoy , Jean Marc Herbert , Maurice Petitou , Constant Van Boeckel , Peter Grootenhuis , Johannes Basten , Cornelia Dreef-Tromp
IPC分类号： A61K3170
CPC分类号： C08B37/006 , C08B37/00
摘要： A synthetic polysaccharide including an antithrombin III binding domain consisting of a concatenation of five monosaccharides supporting a total of two carboxylic acid functions and at least four sulpho groups, said domain being directly bound at the non-reducing end by a thrombin binding domain including a concatenation of 10-25 monosaccharide units selected from hexoses, pentoses or deoxy sugars of which all the hydroxyl groups are etherified by a C1-6 alkyl group or esterified in the form of sulpho groups, as well as salts and particularly pharmaceutically acceptable salts thereof, are disclosed.
摘要翻译： 一种合成多糖，其包括抗凝血酶III结合结构域，由结合总共2个羧酸官能团的5个单糖和至少4个磺基组成，所述结构域在非还原末端通过包含连接的凝血酶结合结构域直接结合 选自己糖，戊糖或脱氧糖的10-25个单糖单元，其全部羟基被C 1-6烷基醚化或以磺酸基形式酯化，以及其盐，特别是其药学上可接受的盐是 披露
-
7.发明授权公开(公告)号：US06528497B1
公开(公告)日：2003-03-04
申请号：US09600506
申请日：2000-09-05
申请人： Johannes Basten , Cornelia Dreef-Tromp , Pierre Alexandre Driguez , Philippe Duchaussoy , Jean Marc Herbert , Maurice Petitou , Constant Van Boeckel
发明人： Johannes Basten , Cornelia Dreef-Tromp , Pierre Alexandre Driguez , Philippe Duchaussoy , Jean Marc Herbert , Maurice Petitou , Constant Van Boeckel
IPC分类号： A61K31715
CPC分类号： C08B37/0063
摘要： Novel synthetic polysaccharides for use in the treatment of pathologies associated with a coagulation dysfunction.
摘要翻译： 用于治疗与凝血功能障碍有关的病理学的新型合成多糖。
-
8.发明授权公开(公告)号：US06541488B1
公开(公告)日：2003-04-01
申请号：US09445555
申请日：2000-02-11
IPC分类号： A61K3170
CPC分类号： A61K31/7024 , A61K31/00 , A61K31/40 , A61K31/435 , A61K31/445 , A61K31/702 , A61K31/715 , A61K45/06 , A61K2300/00
摘要： The invention relates to the use of direct or indirect selective inhibitors of factor Xa acting via antithrombin III, alone or in combination with one or more compounds with anti-platelet aggregation activity, for the preparation of medicines intended to prevent and to treat thromboembolic arterial diseases. The subject of the invention is also pharmaceutical compositions containing one or more direct or indirect selective inhibitors of factor Xa which act via antithrombin III in combination with one or more compounds with anti-platelet aggregation activity, and optionally one or more pharmaceutically acceptable vehicles.
摘要翻译： 本发明涉及通过抗凝血酶III单独或与一种或多种具有抗血小板聚集活性的化合物联合作用的因子Xa的直接或间接选择性抑制剂用于制备旨在预防和治疗血栓栓塞性动脉疾病的药物 本发明的主题还是含有一种或多种直接或间接因子Xa选择性抑制剂的药物组合物，其通过抗凝血酶III与一种或多种具有抗血小板聚集活性的化合物以及任选的一种或多种药学上可接受的载体组合起作用。
-
9.发明授权Associations of active principles containing clopidogrel and an antithrombotic agent 有权含有氯吡格雷和抗血栓药物的活性成分的关联
公开(公告)号：US5989578A
公开(公告)日：1999-11-23
申请号：US117904
申请日：1998-08-12
申请人： Andre Bernat , Jean Marc Herbert , Pierre Savi
发明人： Andre Bernat , Jean Marc Herbert , Pierre Savi
IPC分类号： A61K31/435 , A61K31/00 , A61K31/4353 , A61K31/4365 , A61K31/60 , A61K31/612 , A61K31/616 , A61P5/36 , A61P5/44 , A61P7/00 , A61P7/02 , A61F13/00 , A61F9/02 , A61K9/14 , A61K9/20 , A61K9/64
CPC分类号： A61K31/60 , A61K31/621
摘要： The invention relates to a pharmaceutical composition containing an association of active principles, wherein the active principles are clopidogrel and aspirin, each constituent being present in a free form or in the form of a pharmaceutically acceptable salt.
摘要翻译： PCT No.PCT / FR97 / 00296 Sec。 371日期1998年8月12日 102（e）日期1998年8月12日PCT 1997年2月17日提交PCT公布。 公开号WO97 / 29753 日期1997年8月21日本发明涉及含有活性成分缔合的药物组合物，其中活性成分是氯吡格雷和阿斯匹林，各组分以游离形式或药学上可接受的盐形式存在。
-
10.发明申请USE OF A PYRAZOLE DERIVATIVE FOR PREPARING MEDICINAL PRODUCTS THAT ARE USEFUL IN THE PREVENTION AND TREATMENT OF DYSLIPIDAEMIAS AND OF DISEASES RELATED TO DYSLIPIDAEMIAS AND/OR TO OBESITY 审中-公开使用吡唑衍生物制备有用于预防和治疗白斑病和与紫杉醇有关的疾病和/或肥胖的药物产品公开(公告)号：US20090215755A1
公开(公告)日：2009-08-27
申请号：US12463652
申请日：2009-05-11
申请人： Michele Arnone , Jean Marc Herbert , Hassan Massoud Heshmati , Philip Janiak , Mohammed Bensaid
发明人： Michele Arnone , Jean Marc Herbert , Hassan Massoud Heshmati , Philip Janiak , Mohammed Bensaid
IPC分类号： A61K31/454 , A61P3/04 , A61P3/10 , A61P9/00 , A61K31/549
CPC分类号： A61K31/4178 , A61K31/366 , A61K31/454 , A61K31/5415 , A61K2300/00
摘要： Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidemias and of diseases related to dyslipidemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and hepatic diseases.
摘要翻译： 作为大麻素CB1受体的拮抗剂的单独或与另一活性成分组合的吡唑衍生化合物用于制备可用于预防和治疗血脂异常和与血脂异常和/或肥胖有关的疾病的药物的用途， 如代谢综合征，心血管风险和肝脏疾病。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.034 秒)
